Pregabalin Add-On Titration Trial: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Pregabalin (150 mg - 600 mg/Day) Using a Flexible, Optimized Dose Schedule in Subjects With Partial Seizures.

Trial Profile

Pregabalin Add-On Titration Trial: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Pregabalin (150 mg - 600 mg/Day) Using a Flexible, Optimized Dose Schedule in Subjects With Partial Seizures.

Completed
Phase of Trial: Phase III

Latest Information Update: 12 May 2009

At a glance

  • Drugs Pregabalin (Primary)
  • Indications Partial epilepsies
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 12 May 2009 Actual end date (Aug 2006) added as reported by ClinicalTrials.gov.
    • 01 Mar 2009 Primary endpoint 'Seizure frequency' has been met.
    • 23 May 2007 The expected completion date for this trial is now 1 Aug 2007.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top